Overview

This study aims to explore the relationship between vocal expressions, mood, and cognitive functions during psychedelic experiences. It will specifically investigate whether individuals consuming psilocybin and ketamine, through either single doses or a microdosing regimen, demonstrate unique speech biomarker patterns during and after psychedelic consumption

Additionally, the research will assess how these vocal biomarkers correlate with depression severity, measured by scores on the MADRS scale. Given the well-documented antidepressant properties of psychedelics, and their capacity to alter mood, enhance creativity, cognitive flexibility, and induce profound or mystical experiences, these elements will be evaluated among participants before, during, and after their psychedelic experiences. To the best of the researchers' knowledge, this study will be the first to analyze speech dynamics within psychedelic states and its potential links to changes in mood, creativity, insight, and cognitive processes.

The research team plans to conduct an extensive survey with a broad, global participant base, using a web application that facilitates at-home completion. Participants will undergo established neuropsychological assessments, engage in verbal tasks, respond to relevant survey questions, and provide a voice sample. The study's online and anonymous format aims to increase its accessibility and diversity, enhancing the measurement of the "real-world" impacts of psychedelics on mood and cognition.

Inclusion Criteria:

• 18 years of age or older
• Full legal and mental capacity
• Access to a smartphone or computer with internet for study measures and audio recordings
• Active psilocybin user (microdoser or regular dose)

Exclusion Criteria:

• Clinical diagnosis of bipolar, schizophrenia, or cognitive impairment
• Currently not on anti-psychotic medication or antidepressants
• Lack of English proficiency
• Psychedelic use in the previous month